Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab vs Pembrolizumab in First-line Metastatic NSCLC
NCT05899608Phase 3Active, not recruiting
- Sponsor
- Summit Therapeutics
- Start
- Oct 2023
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Summit Therapeutics. Started Oct 2023; status: active, not recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05899608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05899608.